TATA-box binding protein associated factor 1 likeGenealiases: TAF(II)210 · TAF2A2
Q-omics provides the consensus-scored TAF1L profile across patient tissues and cancer cell-line models. TAF1L expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, TAF1L is differentially expressed in 7, with the highest sampling consensus in COAD. Additionally, TAF1L RNA expression shows 15,179 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KICH, COAD, and THYM as cancer lineages where TAF1L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TAF1L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TAF1L survival associations across molecular data types. TAF1L RNA expression shows survival associations in the most cancer types (18), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TAF1L RNA expression–survival associations across cancer types. High TAF1L expression shows unfavorable associations in KICH, KIRC, LIHC and THCA, but favorable associations in SKCM and PRAD. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify KICH as the clearest survival context for TAF1L RNA expression.
This table summarizes TAF1L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for TAF1L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TAF1L shows higher tumor expression in COAD, LUAD, HNSC, LIHC, LUSC and BLCA. The COAD box plot shows higher TAF1L RNA expression in tumor versus normal tissue (log2 FC = +0.037, t-test p < 0.001).
This table shows molecular features associated with TAF1L in patient tissues and cancer cell lines. In patient samples, TAF1L shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, TAF1L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and LUNG_SCLC.
